Autoimmune Diseases (Lupus / Rheumatoid Arthritis / Gout) C&P Exam Prep

ANA (Antinuclear Antibody) Titer

What it measures: Presence and magnitude of antinuclear antibodies, a hallmark serologic finding in SLE and many other autoimmune conditions.

What to expect: The examiner will review prior lab results and may note titer level and pattern (homogeneous, speckled, etc.). A titer of -1:80 is generally considered positive.

Pain considerations: ANA testing is a blood draw; not directly painful, but active disease causing joint pain or fatigue may make travel to labs difficult - communicate this functional burden.

Anti-dsDNA (Anti-Double-Stranded DNA) Antibody

What it measures: Highly specific marker for SLE; levels often correlate with disease activity and renal flares.

What to expect: The examiner will review prior results. Elevated levels are associated with active lupus nephritis and systemic flares.

Pain considerations: Communicate any functional limitations that prevented timely lab follow-up during flares.

Complement Levels (C3 and C4)

What it measures: Low complement levels indicate complement consumption from immune complex deposition, a sign of active SLE, particularly lupus nephritis.

What to expect: Examiner will review C3 and C4 values. Low levels during flares are clinically significant.

Pain considerations: Document how fatigue from active disease affected your ability to attend lab appointments.

Complete Blood Count (CBC) - Hemoglobin, Hematocrit, WBC, RBC, Platelet Count

What it measures: Evaluates hematologic manifestations of autoimmune disease including hemolytic anemia (low Hgb/Hct), leukopenia/lymphopenia, and thrombocytopenia.

What to expect: The examiner will document any abnormal CBC values. Lymphopenia (<1,500 cells/-L) and thrombocytopenia are specific criteria in the SLE DBQ.

Pain considerations: Fatigue from anemia significantly impacts daily function - describe this as a separate disabling symptom.

Renal Function Panel - BUN, Creatinine, eGFR

What it measures: Assesses kidney function and damage from lupus nephritis or other autoimmune renal involvement.

What to expect: Examiner will document current and historical values. Elevated creatinine, reduced eGFR, and abnormal BUN indicate renal impairment.

Pain considerations: Renal impairment causes fatigue, edema, and hypertension - each of these functional impacts should be separately described.

Urinalysis (with Microscopy)

What it measures: Detects proteinuria, hematuria, hyaline casts, granular casts, and RBC casts - key indicators of lupus nephritis activity.

What to expect: Examiner will review urinalysis results. The DBQ specifically tracks protein, blood, glucose, hyaline casts, granular casts, and microscopic findings.

Pain considerations: Edema from nephrotic syndrome causes pain, difficulty walking, and limits daily activities - describe these impacts specifically.

ESR (Erythrocyte Sedimentation Rate) and CRP (C-Reactive Protein)

What it measures: Non-specific markers of systemic inflammation. Elevated values indicate active disease; used to document flare activity.

What to expect: Examiner will note values relative to normal ranges. ESR is commonly elevated in SLE and RA.

Pain considerations: High ESR and CRP correlate with pain and fatigue severity - describe how inflammation physically felt during those periods.

Joint Range of Motion (ROM) Assessment (for RA / Autoimmune Arthritis)

What it measures: Active and passive ROM of affected joints; evaluated under DeLuca factors for pain, fatigue, weakness, incoordination, and flare-up effects per 38 CFR 4.40 and 4.45.

What to expect: Examiner will measure ROM of affected joints using a goniometer. Both active and passive motion will be tested. Weight-bearing and non-weight-bearing tests may be performed for lower extremity joints per Correia requirements.

Pain considerations: Pain with motion, after motion, and at rest should all be separately described. Fatigue after repetitive use is a DeLuca factor that can support a higher rating even when resting ROM appears adequate.

100%

SLE (DC 6350): Persistent signs and symptoms at the 60% level AND requires regular hospital, residential, or nursing home-level care. OR for Discoid Lupus (DC 7809) / skin ratings: More than 40% of the entire body or more than 40% of exposed areas affected, OR constant or near-constant systemic therapy (immunosuppressives, retinoids, biologics, or oral corticosteroids) required over the past 12 months.

From 38 CFR: 38 CFR 4.88b DC 6350: Persistent signs and symptoms of active disease or complications requiring regular professional supervision. 38 CFR 4.118 DC 7809 via General Rating Formula for Skin: Constant or near-constant systemic therapy required.

60%

SLE (DC 6350): Exacerbations occurring 3 or more times per year, OR; requiring prolonged (6 weeks or more) treatment with systemic corticosteroids or other immunosuppressives, OR; resulting in hospitalization OR; with pronounced involvement of multiple major organs (kidneys, heart, lungs, CNS). For skin (DC 7809): 20-40% of the entire body or 20-40% of exposed areas affected, OR systemic therapy required for a total of 6 weeks or more but not constantly during the past 12 months.

From 38 CFR: 38 CFR 4.88b DC 6350: Exacerbations 3+ per year or prolonged treatment requiring systemic corticosteroids. 38 CFR 4.118 DC 7809: 20-40% BSA or systemic therapy 6+ weeks in 12 months.

40%

SLE (DC 6350): Exacerbations 2 times per year or requiring prolonged corticosteroid/immunosuppressive therapy. For skin (DC 7809): At least 5% but less than 20% of the entire body or at least 5% but less than 20% of exposed areas affected, OR intermittent systemic therapy required for at least 6 weeks in the past 12 months. RA (DC 5002): With constitutional manifestations, significant joint deformity, ankylosis, or other disability.

From 38 CFR: 38 CFR 4.88b DC 6350: Exacerbations 2x/year or requiring prolonged treatment. 38 CFR 4.118 DC 7809: 5-20% BSA or systemic therapy -6 weeks. 38 CFR 4.71a DC 5002: With constitutional manifestations.

10%

SLE (DC 6350): Exacerbations once a year. Skin (DC 7809): Less than 5% of the entire body or less than 5% of exposed areas affected AND no more than topical therapy required during the past 12 months. RA: Occasional exacerbations, use of NSAIDs or disease-modifying agents, minimal functional impairment.

From 38 CFR: 38 CFR 4.88b DC 6350: One exacerbation per year. 38 CFR 4.118 DC 7809: Less than 5% BSA, topical therapy only.

0%

SLE or autoimmune condition that is service-connected but currently in complete remission with no active symptoms, no medications required, and no functional impairment. Condition is noted and rated non-compensably to preserve the service connection in the event of future worsening.

From 38 CFR: 38 CFR 4.88b DC 6350 and 38 CFR 4.118 DC 7809: Condition in complete remission. Service connection preserved at 0%.

Flare-Up Frequency and Severity

How to describe it: Describe exactly how many flares you have had in the past 12 months, how long each lasted, what triggered them, what symptoms occurred, and what medical intervention was required (ER visits, hospitalizations, prednisone bursts, increased immunosuppressive dosing). Use specific dates if possible.

Example: During my worst flare in [month/year], I was bedridden for 14 days with joint pain so severe I could not dress myself, a butterfly rash covering my face and neck, extreme fatigue, a fever of 101.5-F, and my rheumatologist increased my prednisone to 40 mg daily for 3 weeks. I missed 10 consecutive days of work.

Examiner listens for: The examiner needs to document flare frequency (1x/year = 10%, 2x = 40%, 3x+ = 60%) and whether flares require systemic treatment. Vague answers about 'getting worse sometimes' will not satisfy DBQ requirements.

Avoid: Do not say 'I manage okay' or 'I push through it.' State clearly how each flare disabled you and what medical care was required. Do not minimize because you are having a good day at the exam.

Fatigue and Constitutional Symptoms

How to describe it: Describe your fatigue as a separate, disabling symptom distinct from joint pain. Quantify it: rate it on a 0-10 scale on your worst days, describe how many hours per day you can be functional, and identify activities you can no longer perform or complete. Also describe any fevers, unexplained weight loss, and night sweats.

Example: On my worst days - which occur at least [X] times per month - my fatigue is a 9/10. I cannot get out of bed before noon, I cannot cook my own meals, and I require assistance with basic hygiene. Even on moderate days, I am exhausted after 2-3 hours of light activity and must rest for several hours before resuming.

Examiner listens for: Fatigue is a critical functional symptom in autoimmune conditions. The examiner needs concrete examples of how fatigue limits occupational and daily activities. This supports both the overall rating and potential TDIU claims.

Avoid: Do not say 'I am tired' without quantifying the impact. Do not say 'I have good days and bad days' without describing the full spectrum - the VA rates based on the average impact including your worst days, not just your best days.

Joint Pain, Swelling, and Stiffness (Musculoskeletal)

How to describe it: Identify every joint affected by name (bilateral wrists, MCPs, PIPs, knees, ankles, etc.). Describe pain at rest, pain with motion, swelling frequency, and morning stiffness duration. Apply DeLuca factors: describe pain, fatigue, weakness, incoordination, and how symptoms worsen with repetitive use or flares.

Example: During flares, the pain in my bilateral wrists and finger joints is 8/10 at rest and 10/10 with any gripping activity. Morning stiffness lasts 2-3 hours. I cannot open jars, type for more than 10 minutes, or turn a steering wheel. After even brief activity, my joints swell visibly and the pain increases significantly for the next 24 hours.

Examiner listens for: The examiner will document affected joints for the DBQ's joint section. For RA rated under DC 5002, the number of joints affected, functional limitation, and whether constitutional manifestations are present determines the rating level. DeLuca factors - especially pain with motion and after repetitive use - directly affect the rating.

Avoid: Do not perform at your maximum ability during ROM testing if it causes pain. Tell the examiner 'this hurts' during each motion. Do not omit joints that are intermittently affected - all joints affected during flares should be reported.

Skin Manifestations (Rash, Alopecia, Oral Ulcers)

How to describe it: Describe the type, location, frequency, and extent of skin involvement. For malar rash: where it appears, how long it lasts, whether it is photosensitive, and what percentage of your face/exposed skin it covers. For alopecia: how much hair you lose, whether it scars, and the psychological impact. For oral ulcers: frequency, pain level, and impact on eating.

Example: During active flares my butterfly rash covers both cheeks, the bridge of my nose, and spreads to my neck - roughly 15-20% of my exposed facial area. It burns and itches, causes visible disfigurement, and I avoid sun exposure entirely because UV light reliably triggers a full systemic flare within 48 hours. I have had scarring hair loss resulting in visible bald patches approximately [size] that do not regrow.

Examiner listens for: The examiner will document the specific skin areas affected on the DBQ (cheeks, nose, scalp, hands, feet, lips/mouth, chin, ears, etc.) and estimate body surface area involvement. The percentage of BSA involved is the primary driver of skin ratings under DC 7809. Mention all areas affected - the examiner needs to check every applicable box.

Avoid: Do not say 'I get a rash sometimes.' Specify location, extent, frequency, and what aggravates it. Do not omit oral ulcers or scalp involvement - these are separately noted on the DBQ and contribute to the overall picture of active disease.

Organ System Involvement (Renal, Cardiac, Pulmonary)

How to describe it: For each organ system affected, describe when it was diagnosed, what symptoms you experience, what treatments were prescribed, and how it limits your daily function. Renal: swelling, foamy urine, elevated BP, dietary restrictions. Cardiac: chest pain, palpitations, shortness of breath at rest. Pulmonary: shortness of breath with exertion, pleuritic chest pain, reduced exercise tolerance.

Example: Due to lupus nephritis, I have persistent leg swelling to mid-calf requiring compression stockings and diuretics. My blood pressure requires two medications to control. I can walk approximately one block before becoming short of breath. I cannot climb stairs without stopping to rest. On my worst days, the swelling extends to my thighs and I cannot wear shoes.

Examiner listens for: Each organ system involvement is separately documented on the DBQ and can lead to additional separate ratings (e.g., renal under DC 7101, cardiac under appropriate DC, pulmonary under DC 6600-series). Be specific and thorough - the examiner can only check boxes for manifestations that are reported and documented.

Avoid: Do not say 'my kidneys are a little affected.' Give specific numbers when available (creatinine level, 24-hour protein, eGFR). Do not omit symptoms because 'they are being treated' - the treatment requirement itself is evidence of severity.

Medication Burden and Side Effects

How to describe it: List every medication you take for your autoimmune condition, the dose, duration, and reason. Specifically identify oral corticosteroids (prednisone), immunosuppressives (methotrexate, mycophenolate, azathioprine, cyclophosphamide), biologics (Benlysta/belimumab, rituximab), hydroxychloroquine, and any topical agents. Describe side effects that themselves are disabling.

Example: I have been on prednisone ranging from 5 to 40 mg daily for the past 3 years due to recurrent flares. Side effects include weight gain of 35 lbs, avascular necrosis of my right hip requiring monitoring, glucose intolerance, insomnia, and mood disturbances. I also take mycophenolate 1,500 mg twice daily which causes chronic nausea and diarrhea limiting my ability to leave my home reliably.

Examiner listens for: The DBQ has specific checkboxes for oral corticosteroids, immunosuppressives/retinoids, topical corticosteroids, and other immunosuppressive medications - including duration. Prolonged systemic therapy is a direct rating criterion at the 60-100% level. The examiner needs the medication list and duration to complete these fields accurately.

Avoid: Do not forget to list all autoimmune medications including OTC NSAIDs taken for symptom management. Do not understate duration - if you have been on corticosteroids intermittently for years, the total cumulative duration matters. Side effects of medications that themselves cause disability may support secondary service connection claims.

Impact on Work and Daily Activities

How to describe it: Describe in concrete terms how your autoimmune condition prevents or limits work attendance, job performance, and activities of daily living. Use specific examples: missed work days per month, tasks you can no longer perform, accommodations required, inability to sustain full-time employment.

Example: In the past 12 months I have missed approximately [X] days of work due to flares and medical appointments. My employer has placed me on intermittent FMLA. I cannot perform my previous job duties of [specific tasks] due to joint pain, fatigue, and cognitive fog from my condition and medications. On bad weeks, I cannot drive, prepare meals, or perform personal hygiene without assistance.

Examiner listens for: The DBQ has a specific field asking the examiner to describe the impact of the autoimmune disease on occupation and daily activities. This section directly informs TDIU eligibility and the overall rating narrative. Concrete, specific functional limitations are far more persuasive than general statements.

Avoid: Do not say 'I try to stay active.' Do not say you are 'managing' if you are actually struggling. The VA rates based on how your condition actually functions - on your average and worst days - not how optimistically you present yourself on a good exam day.